Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Símbolo de cotizaciónETON
Nombre de la empresaEton Pharmaceuticals Inc
Fecha de salida a bolsaNov 09, 2018
Director ejecutivoMr. Sean E. Brynjelsen
Número de empleados31
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 09
Dirección21925 W Field Pkwy Ste 235
CiudadDEER PARK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal60010-7278
Teléfono18477877361
Sitio Webhttps://etonpharma.com/
Símbolo de cotizaciónETON
Fecha de salida a bolsaNov 09, 2018
Director ejecutivoMr. Sean E. Brynjelsen
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos